Core Insights - Viatris (VTRS) has acquired Tokyo-based Aculys Pharma, focusing on enhancing its Central Nervous System (CNS) portfolio and expanding its presence in Japan and the Asia-Pacific region [1][3][6] Acquisition Details - The acquisition involves an undisclosed upfront payment to Aculys Pharma's shareholders, with additional payments linked to regulatory and commercial milestones, as well as royalties based on net sales [2] - Viatris has secured exclusive rights to develop and commercialize pitolisant and Spydia (diazepam nasal spray) in Japan and select Asia-Pacific markets [1][6][7] Product Information - Pitolisant is a selective/inverse agonist of the histamine H3 receptor, with plans for marketing approval in Japan by the end of 2025 for treating excessive daytime sleepiness (EDS) and cataplexy in narcolepsy patients [4][9] - Spydia, approved in June 2025 in Japan, is the first intranasal anti-seizure medication for status epilepticus, addressing unmet needs in neurological emergencies [7][8] Strategic Rationale - The acquisition aims to leverage Viatris' commercial infrastructure and CNS expertise, aligning with its strategy to grow in high-impact therapeutic areas [9][10] - This move complements Viatris' existing innovative portfolio in Japan, which includes products for various conditions, thereby positioning the company for near- and mid-term growth [10]

Accessibility StatementSkip Navigation PITTSBURGH, Oct. 15, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has acquired Aculys Pharma, Inc., a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions. Viatris received rights to develop and commercialize pitolisant and Spydia, two assets in the Central Nervous System (CNS) therapy area, further expanding Viatris' portfolio of innovative products in ...